Sugi Predict

Sugi Predict / Compounds / SCHEMBL3871649

SCHEMBL3871649

SCHEMBL3871649

COc1ccc(-c2ccc(C(=O)NCCc3ccc(C(C)N4CCCCC4)cc3)cc2)cc1

nearest known ligand 0.55

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 1/20 0.55
▸ LMNA P02545 3/20 0.54
▸ RAB9A P51151 6/20 0.54
▸ MCHR1 Q99705 3/20 0.53
▸ SMN1; SMN2 Q16637 5/20 0.52
▸ MAPT P10636 4/20 0.52
▸ ALDH1A1 P00352 3/20 0.52
▸ POLB P06746 1/20 0.52
▸ TP53 P04637 1/20 0.52
▸ CYP2D6 P10635 1/20 0.51
▸ CHRM1 P11229 1/20 0.51
▸ HTR2A P28223 1/20 0.51
▸ NPC1 O15118 3/20 0.50
▸ NAMPT P43490 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3868681 1.00 KDM4E (0.55) KDM4ELMNARAB9AMCHR1SMN1; SMN2
SCHEMBL3877263 0.99 KDM4E (0.56) KDM4ELMNARAB9AMCHR1SMN1; SMN2
SCHEMBL3879855 0.91 KDM4E (0.54) KDM4ELMNARAB9ASMN1; SMN2MAPT
SCHEMBL3870571 0.89 MCHR1 (0.55) KDM4ELMNARAB9AMCHR1SMN1; SMN2
SCHEMBL3873969 0.89 MCHR1 (0.55) KDM4ELMNARAB9AMCHR1SMN1; SMN2
SCHEMBL3870079 0.89 ALDH1A1 (0.57) KDM4ELMNARAB9AMCHR1SMN1; SMN2
SCHEMBL3870885 0.89 ALDH1A1 (0.57) KDM4ELMNARAB9AMCHR1SMN1; SMN2
SCHEMBL3867758 0.88 TRPV1 (0.52) MCHR1SMN1; SMN2ALDH1A1CYP2D6CHRM1
SCHEMBL3871933 0.88 TRPV1 (0.52) MCHR1SMN1; SMN2ALDH1A1CYP2D6CHRM1
SCHEMBL3869879 0.88 MCHR1 (0.69) LMNARAB9AMCHR1SMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7601868-B2 Such as 4-(cyclopropylmethoxy)-N-(2-{4-[1-(1-pyrrolidinyl)ethyl]phenyl}ethyl)benzamide having melanin-concentrating hormone antagonistic action, for prophylaxis and/or treatment of obesity TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-13 — — US disclosed
US-7601868-B2 Such as 4-(cyclopropylmethoxy)-N-(2-{4-[1-(1-pyrrolidinyl)ethyl]phenyl}ethyl)benzamide having melanin-concentrating hormone antagonistic action, for prophylaxis and/or treatment of obesity TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-13 — — US disclosed
US-7601868-B2 Such as 4-(cyclopropylmethoxy)-N-(2-{4-[1-(1-pyrrolidinyl)ethyl]phenyl}ethyl)benzamide having melanin-concentrating hormone antagonistic action, for prophylaxis and/or treatment of obesity TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-13 — — US disclosed
US-20060128690-A1 Amine derivative TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-06-15 — — US disclosed
EP-1593667-A1 AMINE DERIVATIVE Takeda Pharmaceutical Company Limited (JP) 2005-11-09 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060128690-A1 Amine derivative MC1R, MC2R, MC4R KDM4E 1415/4885LMNA 4333/4885RAB9A 1092/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.